Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
UnitedHealth Group is the largest U.S. health insurer and healthcare services provider, operating through two divisions: UnitedHealthcare (insurance covering 53M Americans across commercial, Medicare Advantage, Medicaid) and Optum (pharmacy benefits via OptumRx handling $140B+ in drug spend, physician practices with 70K+ employed/affiliated doctors, and data/technology services). The company's vertical integration across insurance, care delivery, and pharmacy creates cost advantages and data moats that competitors struggle to replicate.
UnitedHealthcare earns medical loss ratio (MLR) spreads by keeping claims costs below premium revenue, targeting 82-84% MLR in commercial and 85-87% in Medicare Advantage. Optum generates margins through pharmacy spread pricing (difference between reimbursement and drug acquisition costs), capitated care arrangements where it assumes risk for patient populations, and technology licensing. Vertical integration allows the company to capture value across the healthcare chain: insurance premiums fund Optum services, Optum data improves underwriting, and owned physician networks reduce external care costs. Scale advantages include $140B+ OptumRx purchasing power for drug negotiations and 70K+ affiliated physicians enabling care steering.
Medicare Advantage membership growth and Star Ratings (4+ stars unlock bonus payments worth $1K+ per member annually)
Medical loss ratio trends across commercial, Medicare, Medicaid segments (every 100bps MLR change impacts $4B+ in earnings)
OptumHealth value-based care patient additions (now serving 5M+ patients under full/shared risk arrangements)
Regulatory changes to Medicare Advantage reimbursement rates (CMS rate notices drive 3-5% annual revenue swings)
Pharmacy benefit contract renewals and drug pricing dynamics (biosimilar adoption, GLP-1 utilization trends)
DOJ/regulatory scrutiny of vertical integration and physician practice acquisitions
Medicare Advantage reimbursement cuts from federal deficit reduction efforts (program represents $450B+ in annual government spending, political target for cost containment)
Single-payer or public option proposals that would eliminate/reduce private insurance market (Medicare-for-All would destroy 65% of revenue base)
Increasing regulatory scrutiny of vertical integration, particularly DOJ challenges to physician practice acquisitions and pharmacy benefit manager practices
Drug pricing reform (Inflation Reduction Act Medicare negotiation, PBM spread transparency mandates) compressing OptumRx margins
Amazon/CVS Health vertical integration creating alternative care delivery models (Amazon Clinic, Oak Street Health acquisition by CVS)
Employer direct contracting with health systems bypassing traditional insurers (Boeing, Walmart direct-to-provider arrangements)
Medicare Advantage margin compression from Humana, CVS/Aetna, Centene competition driving Star Ratings arms race and benefit richness
Technology disruptors in prior authorization, claims processing reducing barriers to entry for new managed care entrants
Medical claims payable volatility creating reserve development risk (adverse development would require $2B+ charges as seen in prior years)
Goodwill impairment risk from $50B+ in intangible assets related to Optum acquisitions if value-based care economics deteriorate
Regulatory capital requirements for insurance subsidiaries limiting dividend capacity to parent company during stress scenarios
moderate - Commercial insurance membership tied to employer-sponsored coverage, making it sensitive to employment levels (every 1% unemployment increase impacts ~500K covered lives). However, counter-cyclical Medicaid enrollment rises during recessions as individuals lose employer coverage. Medicare Advantage is GDP-insensitive (age-driven enrollment). Medical utilization increases during economic expansions as consumers defer less care, compressing MLRs. Optum's elective procedures and technology spending are pro-cyclical.
Rising rates benefit investment income on $80B+ insurance float (every 100bps rate increase adds $800M+ annual investment income), partially offsetting underwriting pressure. However, higher rates increase discount rates applied to long-duration medical liabilities and compress valuation multiples for healthcare services peers. Debt service costs are modest given 0.78x debt/equity ratio. Rate cuts would pressure investment yields while potentially stimulating elective procedure volumes.
Moderate exposure through provider payment risk (hospitals/physicians owed $25B+ in claims payable) and pharmacy receivables. Economic stress increases bad debt from individual exchange members and Medicaid reimbursement delays from state budget pressures. Value-based care arrangements create credit exposure to physician practice financial performance. Investment portfolio includes $15B+ in corporate bonds sensitive to credit spreads.
value - Defensive healthcare exposure with 6.1% FCF yield trading at 0.6x sales (below historical 0.8-1.0x range) following 45% drawdown. Attracts long-term value investors seeking recession-resistant cash flows and dividend growth (2.5% yield with 15-year increase streak). Recent underperformance creates contrarian opportunity if regulatory/MLR headwinds stabilize. Not a growth stock given mature market penetration, but Optum's 15%+ growth provides upside optionality.
moderate - Beta typically 0.7-0.9 given defensive healthcare characteristics, but recent 45% decline reflects elevated regulatory/political risk premium. Quarterly earnings volatility driven by medical cost surprises (flu severity, COVID resurgence, deferred care normalization). Medicare Advantage rate announcements create discrete 5-10% single-day moves. Less volatile than biotech/devices but more volatile than utilities.
